MA31412B1 - Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane - Google Patents

Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane

Info

Publication number
MA31412B1
MA31412B1 MA31715A MA31715A MA31412B1 MA 31412 B1 MA31412 B1 MA 31412B1 MA 31715 A MA31715 A MA 31715A MA 31715 A MA31715 A MA 31715A MA 31412 B1 MA31412 B1 MA 31412B1
Authority
MA
Morocco
Prior art keywords
azonia
ylcarbamoyl
isoxazol
acetoxy
bicyclo
Prior art date
Application number
MA31715A
Other languages
English (en)
Inventor
Stephanie Monnier
Gerhard Muhrer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31412B1 publication Critical patent/MA31412B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE FORME CRISTALLINE POLYMORPHE INNOVANTE DU BROMURE DE (R)-3-(2-HYDROXY-2,2-DIPHÉNYL-ACÉTOXY)-1-(ISOXAZOL- 3-YLCARBAMOYL- MÉTHYL)-1-AZONIA- BICYCLO- [2.2.2] OCTANE, APPELÉE FORME CRISTALLINE TALPHA. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE LADITE FORME CRISTALLINE ET L'UTILISATION DE LA FORME CRISTALLINE EN TANT QUE MATIÈRE ACTIVE DE MÉDICAMENTS DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES OU DE MALADIES OBSTRUCTIVES DES VOIES RESPIRATOIRES.
MA31715A 2006-08-31 2009-03-13 Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane MA31412B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119883A EP1900737A1 (fr) 2006-08-31 2006-08-31 Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Publications (1)

Publication Number Publication Date
MA31412B1 true MA31412B1 (fr) 2010-06-01

Family

ID=37685707

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31715A MA31412B1 (fr) 2006-08-31 2009-03-13 Polymorphe du bromure de (r)-3(2-hydroxy-2,2 diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2] octane

Country Status (21)

Country Link
US (1) US20090264461A1 (fr)
EP (2) EP1900737A1 (fr)
JP (1) JP2010501611A (fr)
KR (1) KR20090051110A (fr)
CN (1) CN101506205A (fr)
AR (1) AR062582A1 (fr)
AU (1) AU2007291515A1 (fr)
BR (1) BRPI0716205A2 (fr)
CA (1) CA2660983A1 (fr)
CL (1) CL2007002524A1 (fr)
GT (1) GT200900044A (fr)
IL (1) IL196808A0 (fr)
MA (1) MA31412B1 (fr)
MX (1) MX2009002300A (fr)
NO (1) NO20091231L (fr)
PE (1) PE20080985A1 (fr)
RU (1) RU2009111390A (fr)
TN (1) TN2009000069A1 (fr)
TW (1) TW200817399A (fr)
WO (1) WO2008025541A1 (fr)
ZA (1) ZA200900449B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
RU2463048C2 (ru) * 2006-11-23 2012-10-10 Эргонекс Фарма Гмбх Фармацевтические композиции для лечения капиллярной артериопатии

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.

Also Published As

Publication number Publication date
PE20080985A1 (es) 2008-09-05
AR062582A1 (es) 2008-11-19
BRPI0716205A2 (pt) 2013-11-12
CL2007002524A1 (es) 2008-07-11
EP2064210A1 (fr) 2009-06-03
MX2009002300A (es) 2009-03-20
GT200900044A (es) 2012-01-16
TW200817399A (en) 2008-04-16
EP1900737A1 (fr) 2008-03-19
KR20090051110A (ko) 2009-05-20
TN2009000069A1 (en) 2010-08-19
JP2010501611A (ja) 2010-01-21
IL196808A0 (en) 2009-11-18
NO20091231L (no) 2009-03-25
CN101506205A (zh) 2009-08-12
US20090264461A1 (en) 2009-10-22
ZA200900449B (en) 2010-01-27
RU2009111390A (ru) 2010-10-10
AU2007291515A1 (en) 2008-03-06
WO2008025541A1 (fr) 2008-03-06
CA2660983A1 (fr) 2008-03-06

Similar Documents

Publication Publication Date Title
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
BRPI0410711A (pt) novos compostos
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
WO2007127505A3 (fr) Composés chimiques
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
MA32787B1 (fr) Peptides antiviraux therapeutiques
FR16C0029I2 (fr) Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EA200300713A1 (ru) Производные бензимидазола и пиридилимидазола в качестве лигандов рецепторов гамма-аминомасляной кислоты
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
NO20022095L (no) Heterocyklisk substituerte pyrazoloner
MA30337B1 (fr) Anticorps
MA30289B1 (fr) Dérivés d'amines
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
WO2007062999A3 (fr) Derives de indole-2-yl amide substitues en 1,5